Acarbose: An α-glucosidase inhibitor

American Journal of Health-System Pharmacy

Volumn 53, Issue 19, 1996, Pages 2277-2290

  Martin, Anne E ^a,b,c   Montgomery, Patricia A ^b,d,e  

^a Educational Development   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UMHS   (United States)

^e Department of Pharmacy Practice   (United States)

Author keywords

Acarbose; Antidiabetic agents; Clinical studies; Contraindications; Diabetes mellitus; Dosage; Drug administration; Drug interactions; Mechanism of action; Pharmacokinetics; Toxicity

Indexed keywords

ACARBOSE; ACTIVATED CARBON; ALPHA GLUCOSIDASE INHIBITOR; AMYLASE; CORTICOSTEROID; GLIBENCLAMIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIPID; METFORMIN; ORAL ANTIDIABETIC AGENT; PANCREATIN; PLACEBO; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TOLBUTAMIDE;

ABDOMINAL PAIN; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; NONHUMAN; ORAL DRUG ADMINISTRATION; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW;

EID: 0029796711     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.19.2277     Document Type: Review

References (111)

1. Type 2 diabetes or NIDDM: looking for a better name. Lancet. 1989; 1:589-91. Editorial.
2. Van der Veen EA. Epidemiology of diabetes mellitus and risk factors for end-organ disease. Postgrad Med J. 1988; 64(Suppl 3):5-9.
3. Alberti KG. Problems related to definitions and epidemiology of type 2 (non-insulin-dependent) diabetes mellitus: studies throughout the world. Diabetologia. 1993; 36:978-84.
4. Ericksson J, Franssila-Kallunki A, Edstranc A et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 1989; 321:337-43.
5. Halter JB, Graf RJ, Porte D. Potentiation of insulin secretory responses by plasma glucose levels in man: evidence that hyperglycemia in diabetes compensates for impaired glucose potentiation. J Clin Endocrinol Metab. 1979; 48:946-54.
6. DeFronzo RA. The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes. 1988; 37:667-87.
7. Martin BC, Warram JH, Krowlewski AS et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 1992; 340:925-9.
8. Wolffenbuttel BH, Van Haeften TW. Non-insulin-dependent diabetes mellitus: defects in insulin secretion. Eur J Clin Invest. 1993; 23:69-79.
9. Kahn CR. Insulin action, diabetogenesis and the cause of type II diabetes. Diabetes. 1994; 17:1093-9.
10. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet function and insulin resistance: implications for the management of diabetes. Diabetologia. 1985; 28:119-21.
11. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990; 13:610-30.
12. Yki-Jarvinen H, Young AA, Lamkin C et al. Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest. 1987; 79:1713-9.
13. Greene DA, Sima AA, Stevens MJ et al. Complications: neuropathy, pathogenic considerations. Diabetes Care. 1992; 15:1902-25.
14. Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes. 1994; 43:836-41.
15. Wolffenbuttel BH, van Haeften TW. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). Drugs. 1995; 50:263-88.
16. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86.
17. Hoogwerf BH, Brouhard BH. Glycemic control and complications of diabetes mellitus: practical implications of the Diabetes Control and Complications Trial (DCCT). Cleve Clin J Med. 1994; 61:34-7
18. Stout RW. Overview of the association between insulin and atherosclerosis. Metabolism. 1985; 34(Suppl 1):7-12.
19. Jarrett RJ. Is insulin atherogenic? Diabetologia. 1988; 31:71-5.
20. Stern MP. The insulin resistance syndrome: the controversy is dead, long live the controversy! Diabetologia. 1994; 37:956-8.
21. Bernhard H. Long-term observations on oral hypoglycemic agents in diabetes: the effect of carbutamide and tolbutamide. Diabetes. 1965; 14:59-70.
22. Singer DL, Hurwitz D. Long-term experience with sulfonylureas and placebo. N Engl J Med. 1967; 277:450-6.
23. Sonksen PH, Lowry C, Perkins JR et al. Non-insulin-dependent diabetes: 10-year outcome in relation to initial response to diet and subsequent sulfonylurea therapy. Diabetes Care. 1984; 7(Suppl 1):59-66.
24. American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care. 1993; 16:1517-20.
25. Morgensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984; 310:356-60.
26. Jarrett RJ. Why is insulin not a risk factor for coronary heart disease? Diabetologia. 1994; 37:945-7.
27. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia. 1994; 37:948-52.
28. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diabetes diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995; 310:83-8.
29. Clissold SP, Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1988; 35:214-43.
30. Caspary WF, Lembcke B, Creutzfeldt W. Inhibition of human intestinal α-glucoside hydrolase activity by acarbose and clinical consequences. In: Creutzfeldt W, ed. Proceedings of the first international symposium on acarbose. Amsterdam, Netherlands: Excerpta Medica; 1982:27-37.
31. Hiele M, Ghoos Y, Rutgeerts P et al. Effects of acarbose on starch hydrolysis: study in healthy subjects, ileostomy patients, and in vitro. Dig Dis Sci. 1992; 37:1057-64.
32. Jenkins DJ, Taylor TF, Goff DV et al. Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes. 1981; 30:951-4.
33. Bischoff H. Pharmacology of α-glucosidase inhibition. Eur J Clin Invest. 1994; 24(Suppl 3):3-10.
34. Wolever TM, Radmard R, Chiasson JL et al. One-year acarbose treatment raises fasting serum acetate in diabetic patients. Diabetic Med. 1995; 12:164-72.
35. Lebovitz HE. Oral antidiabetic agents: the emergence of α-glucosidase inhibitors. Drugs. 1992; 44(Suppl 3):21-8.
36. Hoffman J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients: the Essen study. Diabetes Care. 1994; 17:561-6.
37. Coniff RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1994; 154:2442-8.
38. Coniff RF, Shapiro JA, Seaton TB et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995; 98:443-51.
39. Chiasson JL, Josse RG, Hunt JA et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med. 1994; 121:928-35.
40. Santeusanio F, Compagnucci P. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus. Drug Safety. 1994; 11:432-44.
41. Coniff RF, Shapiro JA, Robbins D et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care. 1995; 18:817-24.
42. Buchanan DR, Collier A, Rodrigues E et al. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetics. Eur J Clin Pharmacol. 1988; 34:51-3.
43. Rodier M, Richard JL, Monnier L et al. Effect of long term acarbose (Bay g 5421) on metabolic control of non insulin dependent (type II) diabetes mellitus. Diabete Metab. 1988; 14:12-4.
44. Hanefeld M, Fischer S, Schultze J et al. Potential use of acarbose as first line drug in non-insulin dependent diabetes mellitus insufficiently treated with diet alone. Diabetic Nutr Metab. 1990; 3(Suppl 1):51-7.
45. Reaven GM, Lardinois CK, Greenfield MS et al. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care. 1990; 13(Suppl 3):32-6.
46. Zimmerman BR. Preventing long term complications: implications for combination therapy with acarbose. Drugs. 1992; 44(Suppl 3):54-9.
47. Goke B, Herrmann C, Goke R et al. Intestinal effects of α-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest. 1994; 24(Suppl 3):25-30.
48. Uttenthal LO, Ukponmwam OO, Ghiglione M et al. Acute and short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man. Dig Dis Sci. 1987; 32:139-44.
49. Jenney A, Proietto J, O'Dea K et al. Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity. Diabetes Care. 1993; 16:499-502.
50. Balfour JA, McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs. 1993; 46:1025-54.
51. Leonhardt W, Hanefeld M, Fischer S et al Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment. Arzneimittelforschung. 1991; 41:735-8.
52. Couet C, Ulmer M, Hamdaoui M et al. Metabolic effects of acarbose in young healthy men. Eur J Clin Nutr. 1989; 43:187-96.
53. Hanefeld M, Fischer S, Schultze J et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care. 1991; 14:732-7.
54. Tuomilehto J, Pohjola M, Lindstrom J et al. Acarbose and nutrient intake in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract. 1994; 26:215-22.
55. Putter J. Studies on the pharmacokinetics of acarbose in humans. In: Brodbeck U, ed. Enzyme inhibitors. Weinheim, Germany: Verlag Chemie; 1980:139-51.
56. Putter J, Keup U, Krause HP et al. Pharmacokinetics of acarbose. In: Creutzfeldt W, ed. Proceedings of the first international symposium on acarbose. Amsterdam, Netherlands: Excerpta Medica; 1982:38-42.
57. 14C] acarbose to rats, dogs and man. Arzneimittelforschung. 1989; 39:1254-60.
58. Muller FO, Hillebrand I. Acarbose (BAY g 5421) kinetics in healthy volunteers. Acta Pharmacol Toxicol. 1986; 59(Suppl V):303. Abstract.
59. Precose package insert. West Haven, CT: Bayer Corporation. 1995 Oct.
60. Hotta N, Kakuta H, Saho T et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabetic Med. 1993; 10:134-8.
61. Scott RS, Knowles RL, Beaven DW. Treatment of poorly controlled non-insulin-dependent diabetic patients with acarbose. Aust N Z J Med. 1984; 14:649-54.
62. Hotta N, Kakuta H, Koh N et al. The effect of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy. Diabetic Med. 1993; 10:355-8.
63. Coniff RF, Shapiro JA, Seaton TB et al. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care. 1995; 18:928-31.
64. Johansen K. Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics: a double-blind cross-over comparison of an α-glucosidase inhibitor with metformin. Diabete Metab. 1984; 10:219-23.
65. Bayraktar M, Adalar N, Van Thiel DH. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care. 1996; 19:252-4.
66. Schwedes U, Petzoldt R, Hillebrand I et al. Comparison of acarbose and metformin treatment in non-insulin-dependent diabetic outpatients. In: Creutzfeldt W, ed. Proceedings of the first international symposium on acarbose. Amsterdam, Netherlands: Excerpta Medica; 1982:313-6.
67. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103-17.
68. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1994; 17:616-23.
69. Glucophage package insert. Princeton, NJ: Bristol-Myers Squibb Company. 1995 Nov.
70. Viviani GL, Camogliano L, Borgoglio MG et al. Acarbose treatment in insulin-dependent diabetics. Curr Ther Res. 1987; 42:1-11.
71. Rios MS. Acarbose and insulin therapy in type I diabetes mellitus. Eur J Clin Invest. 1994; 24(Suppl 3):36-9.
72. Schrezenmeir J, Kasper H. Therapeutic effect of acarbose in reactive hypoglycaemia. In: Creutzfeldt W, ed. Proceedings of the first international symposium on acarbose. Amsterdam, Netherlands: Excerpta Medica; 1982:530-5.
73. Richard JL, Rodier M, Monnier L et al. Effect of acarbose on glucose and insulin response to sucrose load in reactive hypoglycemia. Diabete Metab. 1988; 14:114-8.
74. Lyons TJ, McLouglin JC, Shaw C et al. Effect of acarbose on biochemical responses and clinical symptoms in dumping syndrome. Digestion. 1985; 31:243-52.
75. Noyon R, Pagano Mirani-Oostdijk C, van Gent CM et al. Long-term effect of acarbose on diurnal serum triglyceride, glucose, insulin and adipose tissue lipoprotein levels in patients with primary endogenous hypertriglyceridaemia, with or without type II diabetes. Neth J Med. 1986; 29:157-64.
76. Hollander P. Safety profile of acarbose, an α-glucosidase inhibitor. Drugs. 1992; 44(Suppl 3):47-53.
77. Hillebrand I, Boehme K. Clinical studies on acarbose during 5 years. In: Creutzfeldt W, ed. Proceedings of the first international symposium on acarbose. Amsterdam, Netherlands: Excerpta Medica; 1982:445-50.
78. Toeller M. Nutritional recommendations for diabetic patients and treatment with α-glucosidase inhibitors. Drugs. 1992; 44(Suppl 3):13-20.
79. Sailer D, Roeder G. Treatment of non-insulin dependent diabetics with a new glucosidase inhibitor (Bay g 5421). Arzneimittelforschung. 1980; 30:2181-5.
80. Van Gaal L, Nobels F, De Leeuw I. Effects of acarbose on carbohydrate metabolism, electrolytes, minerals and vitamins in fairly well-controlled non-insulin-dependent diabetes mellitus. Z Gastroenterol. 1991; 29:642-4.
81. William-Olosson T, Krotkiewski M, Sjostrom L. Relapse-reducing effects of acarbose after weight reduction in severely obese subjects. J Ob Weight Reduc. 1985; 5:125-45.
82. Scheen AJ, Magalhaes AC, Salvatore T et al. Reduction of the acute bioavailability of metformin by the α-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest. 1994; 24(Suppl 3):50-4.
83. Hillebrand I, Graefe KH, Bischoff H et al. Serum digoxin and propranolol levels during acarbose treatment. Diabetologia. 1981; 21:282.
84. Gerard J, Lefebvre PJ, Luyckx AS. Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics. Eur J Clin Pharmacol. 1984; 27:233-6.
85. Pinquier JL, Pello JY, Rey E et al. Effect of acarbose repeated dosing on antipyrine test in healthy volunteers. In: Lefebvre PJ, Stnadl E, eds. New aspects in diabetes: treatment strategies with alpha-glucosidase inhibitors. Berlin, Germany: DeGruyter; 1992:291-4.
86. Scheen AJ, Lefebvre PJ. Antihyperglycemic agents: drug interactions of clinical importance. Drug Safety. 195; 12:32-45.
87. Lembcke B, Caspary WF, Folsch UR et al. Influence of neomycin on postprandial metabolic changes and side-effects of an α-glucosidehydrolase inhibitor (BAY g 5421). In: Creutzfeldt W, ed. Frontiers of hormone research. Vol 7. The entero-insular axis. Basel, Switzerland: S. Karger; 1980:294-5.
88. Crapo PA. Use of alternative sweeteners in diabetic diet. Diabetes Care. 1988; 11:174-82.
89. 14C] acarbose to rats and dogs. Arzneimittelforschung. 1989; 39:1254-60.
90. Toeller M. α-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur J Clin Pharmacol. 1994; 24(Suppl 3):31-5.
91. Worlicek H, Schneider M, Kolb S et al. Treatment of non-insulin-dependent diabetic adults with acarbose: the effect of dosage division. In: Creutzfeldt W, ed. Proceedings of the first international symposium on acarbose. Amsterdam, Netherlands: Excerpta Medica; 1982:313-6.
92. Anon. Acarbose for diabetes mellitus. Med Lett Drugs Ther. 1996; 38:9-10.
93. American Diabetes Association. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care. 1995; 18:1510-8.
94. Campbell IW, Menzies DG, Chalmers J et al. One-year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab. 1994; 20:394-400.
95. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995; 333:541-9.
96. Hermann LS, Schersten B, Bitzen PO et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care. 1994; 17:1100-9.
97. Cohen MP, Klepser H, Wu VY. Effect of alpha-glucosidase inhibition on the nonenzymatic glycation of glomerular basement membrane. Gen Pharmacol. 1991; 22:511-5.
98. Sima AA, Chakrabarti S. Long-term suppression of postprandial hyperglycemia with acarbose retards the development of neuropathies in the BB/W rat. Diabetologia. 1992; 35:325-30.
99. Russell JC, Koeslag DG, Dolphin PJ et al. Beneficial effects of acarbose in the atherosclerosis-prone JCR: LA-corpulent rat. Metabolism. 1993; 42:218-23.
100. Ryu JE, Howard G, Craven TE et al. Postprandial triglyceridemia and carotid atherosclerosis in middle aged subjects. Stroke. 1992; 23:823-8.
101. Simons LA, Dwyer T, Simons J et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis. 1987; 65:181-9.
102. McEvoy GK, ed. AHFS drug information 96. Bethesda, MD: American Society of Health-System Pharmacists; 1996:2294-313.
103. Gray H, O'Rahilly S. Toward improved glycemic control in diabetes: what's on the horizon? Arch Intern Med. 1995; 155:1137-42.
104. Lefebvre PJ, Scheen AJ. The use of acarbose in the prevention and treatment of hypoglycaemia. Eur J Clin Invest. 1994; 24(Suppl 3):40-4.
105. Bennett PH. Definition, diagnosis and classification of diabetes mellitus and impaired glucose tolerance. In: Kahn CR, Weir GC, eds. Joslin's diabetes mellitus. 13th ed. Philadelphia: Lea & Febiger; 1994:193-200.
106. Jarrett RJ, Keen H, Fuller JH et al. Worsening to diabetes in men with impaired glucose tolerance ("borderline diabetes"). Diabetologia. 1979; 16:25-30.
107. Saad MF, Knowler WC, Pettitt DJ et al. The natural history of impaired glucose tolerance in Pima Indians. N Engl J Med. 1988; 319:1500-6.
108. Jarrett RJ, Keen H, McCartney P. The Whitehall Study: ten-year follow up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death. Diabetic Med. 1984; 1:279-83.
109. Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes. Diabetologia. 1982; 22:73-8.
110. Sarto G, Scherstein B, Carlstrom S. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes. 1980; 29:41-9.
111. Anon. Bayer Precose ability to delay or prevent onset of type II diabetes will be studied in large trial of patients with impaired glucose tolerance. FDC Rep. 1995; 57(Dec Suppl):3-4.